Quality of life in thyroid cancer
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Quality of life in thyroid cancer. / Watt, Torquil; Christoffersen, Thea; Brogaard, Mathilde Borring; Bjorner, Jakob Bue; Bentzen, Jens; Hahn, Christoffer Holst; Nygaard, Birte; Feldt-Rasmussen, Ulla.
I: Best Practice & Research: Clinical Endocrinology & Metabolism, Bind 37, Nr. 1, 101732, 2023.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Quality of life in thyroid cancer
AU - Watt, Torquil
AU - Christoffersen, Thea
AU - Brogaard, Mathilde Borring
AU - Bjorner, Jakob Bue
AU - Bentzen, Jens
AU - Hahn, Christoffer Holst
AU - Nygaard, Birte
AU - Feldt-Rasmussen, Ulla
N1 - Publisher Copyright: © 2023
PY - 2023
Y1 - 2023
N2 - To explore the impact of differentiated thyroid cancer (DTC) on quality of life (QoL) a clinical analytical framework was developed. Based on the clinical analytical framework, a systematic literature search was performed to identify studies applying patient-reported outcomes (PRO) instruments among patients with DTC. Subsequently, the scope was narrowed down to studies comparing scores on the Medical Outcomes Study (MOS) Short form 36 (SF-36) to a reference population (clinical interpretability criterion). Further, the currently available thyroid cancer (TC) specific QoL PROs were review in accordance with the standards of the International Society of Quality of Life Research. In the initial search, 213 studies were included. The additional ‘clinical interpretability’-criteria, limited the final study sample to 16 studies, 13 cross-sectional and 3 longitudinal. QoL was impacted across all SF-36 scales. The impact was generally modest and the impact was impeded by time since diagnosis and treatment. Four TC specific instruments were identified. Generally, the documentation of their measurement properties, particularly content validity and clinical validity, including substantial quantitative validation, was scarce. As was the cross-cultural applicability of the currently available instruments. This restricted, focused, clinically founded review showed an impact on a broad range of QoL issues. There is a need for large-scale measurement of QoL outcome longitudinally, using well-validated PRO instruments in order to identify with certainty the impact on subgroups.
AB - To explore the impact of differentiated thyroid cancer (DTC) on quality of life (QoL) a clinical analytical framework was developed. Based on the clinical analytical framework, a systematic literature search was performed to identify studies applying patient-reported outcomes (PRO) instruments among patients with DTC. Subsequently, the scope was narrowed down to studies comparing scores on the Medical Outcomes Study (MOS) Short form 36 (SF-36) to a reference population (clinical interpretability criterion). Further, the currently available thyroid cancer (TC) specific QoL PROs were review in accordance with the standards of the International Society of Quality of Life Research. In the initial search, 213 studies were included. The additional ‘clinical interpretability’-criteria, limited the final study sample to 16 studies, 13 cross-sectional and 3 longitudinal. QoL was impacted across all SF-36 scales. The impact was generally modest and the impact was impeded by time since diagnosis and treatment. Four TC specific instruments were identified. Generally, the documentation of their measurement properties, particularly content validity and clinical validity, including substantial quantitative validation, was scarce. As was the cross-cultural applicability of the currently available instruments. This restricted, focused, clinically founded review showed an impact on a broad range of QoL issues. There is a need for large-scale measurement of QoL outcome longitudinally, using well-validated PRO instruments in order to identify with certainty the impact on subgroups.
KW - differentiated thyroid cancer
KW - patient experiences
KW - patient reported outcomes
KW - quality of life
U2 - 10.1016/j.beem.2023.101732
DO - 10.1016/j.beem.2023.101732
M3 - Review
C2 - 36732089
AN - SCOPUS:85147268101
VL - 37
JO - Best Practice and Research in Clinical Endocrinology and Metabolism
JF - Best Practice and Research in Clinical Endocrinology and Metabolism
SN - 1521-690X
IS - 1
M1 - 101732
ER -
ID: 397016767